The Food and Drug Administration on Monday approved Culver City-based ImmunityBio’s treatment for bladder cancer.
Autoimmune Disorders: Bristol Myers Squibb has entered into a research agreement with Repertoire to develop vaccines for ...
The agency greenlit the drug, which will be marketed as Beqvez, for adults with moderate to severe hemophilia B.
The U.S. health regulator on Monday approved ImmunityBio's combination therapy to treat a type of bladder cancer, marking an ...
X4 Pharmaceuticals said on Monday the U.S. FDA has approved its therapy to treat a rare genetic immunodeficiency disease in ...
A California-based immunotherapy company with local operations received good news this week that the U.S. Food and Drug Administration has approved its bladder cancer treatment drug. ImmunityBio Inc.
The FDA has approved a first-in-class bladder cancer drug. Anktiva (interleukin (IL)-15 superagonist nogapendekin alfa inbakicept-pmln) administered with bacillus Calmette-Guérin was approved for ...
Labcorp’s diagnostic assay will act as a companion diagnostic for Pfizer’s recently approved haemophilia B gene therapy ...
MorphoSys faces safety concerns over pelabresib, a myelofibrosis treatment. Physicians report patients transitioning rapidly ...
The US Food and Drug Administration has approved Esprit BTK everolimus-eluting scaffold system for chronic limb-threatening ...
The newly approved oral medication Pivya provides women with another option for treating uncomplicated urinary tract ...
The US Food and Drug Administration (FDA ... non–muscle-invasive bladder cancer carcinoma in situ with or without Ta or T1 papillary disease. The FDA declined an initial approval for the ...